fashion -WSS

fashion

author：Wikipedia 2025-08-26 01:32:57 - browse：733

A judge ruled that Welsh Carson won't have to face antitrust allegations about its anesthesiology practice. Adobe

Welsh, Carson, Anderson & Stowe has wiggled out of the grasp of the Federal Trade Commission, but the private equity firm’s anesthesia company, U.S. Anesthesia Partners, still must face the agency’s antitrust case, a judge ruled last week.

The FTC alleged last year that the anesthesiology network monopolized markets in Texas to drive up prices, but took the unusual step of attaching Welsh Carson as a defendant with USAP. Dismissing Welsh Carson from the case was a victory for the private equity firm and, more broadly, other firms worried that the Biden administration would try to hold them responsible for anything their portfolio companies do.

But the allegations against USAP didn’t disappear, which will keep up scrutiny on companies that have made a push to acquire numerous physician groups.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Hospitals warn Medicare's drug payment fix is ‘unlawful’

Wikipedia

WSS

Too many hospitalized Covid

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Emergency medicine has repudiated 'excited delirium.' Now what?

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Testing for cancer recurrence creates a new limbo for patients

hotspot

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

focus

Jerome Adams on the need for new antivirals for Covid

Telehealth options flood the market as retailers push virtual care

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Eli Lilly to pay $200M for Beam’s stake in gene

23andMe had bad news about my health. I wish a person had delivered it

First Opinion Podcast: How to protect health care in times of war

Psychedelics group wrestles with new pharma identity

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

How to save PrEP access — and even expand it

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Wikipedia

STAT Boddities: What happens to the brain when we get scared?

Paying for Covid pills will soon shift to insurers

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

Too many hospitalized Covid

Cassava reveals details — and problems — with Alzheimer's study

Too many hospitalized Covid

hotspot

knowledge

Wikipedia

hotspot